Dieppe, Canada Clinical Trials

A listing of Dieppe, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Featured trial
Sickle Cell Disease Study: Own Your Health, Share Your Story with PicnicHealth

Get all of your medical records in one secure account and contribute to important real-world Sickle Cell research with PicnicHealth. If you have Sickle Cell, you get $50 for signing up and a free lifetime access to your medical records.   Visit this link to learn more and sign up. …

Online studies
PicnicHealth
(online study) Contact site
  • 11 views
  • 04 Aug, 2022
  • 1 location
  • Online study
Featured trial
Caregiver-Provided Life Review for Persons with Dementia

This study, Caregiver-Provided Life Review (C-PLR) is created based on Life Review therapy. It is for persons living with early-stage dementia along with mild depressive symptoms who are 65 years or older, community-dwellers or the residents of senior housing, independent or assisted living facilities conducted by their family members (18 …

Online studies
dementia
depression
Accepts healthy volunteers
Online Study Center
(online study) Contact site
  • 547 views
  • 09 Aug, 2022
  • 1 location
  • Online study
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder cancer
bladder carcinoma
metastatic urothelial carcinoma
urothelial carcinoma
Moncton Hospital- Horizon Health Network
 (2.7 away) Contact site
  • 243 views
  • 10 May, 2022
  • +63 other locations
Objective, Passive Assessment of LRRK2 Carriers (OPAL)

This study is currently only open to active participants in the University of Rochester’s VALOR-PD study. The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless …

Online studies
movement disorder
University of Rochester
(online study) Contact site
  • 8 views
  • 12 May, 2022
  • 1 location
  • Online study
A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion through an interactive voice …

Regional health authority A vitalite health network
 (1.8 away) Contact site
  • 0 views
  • 14 Jul, 2022
  • +135 other locations
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Novartis Investigative Site
 (1.8 away) Contact site
  • 1 views
  • 20 Jul, 2022
  • +396 other locations
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

The Moncton Hospital
 (2.8 away) Contact site
  • 4 views
  • 25 Jul, 2022
  • +508 other locations
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC …

Moncton Hospital ( Site 0107)
 (2.8 away) Contact site
  • 19 views
  • 25 Jul, 2022
  • +109 other locations
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary …

G A Research Associates ( Site 0652)
 (4.9 away) Contact site
  • 6 views
  • 29 Jul, 2022
  • +318 other locations
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. (DIRECTION)

This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each …

Moncton Hospital
 (1.5 away) Contact site
  • 73 views
  • 09 Aug, 2022
  • +45 other locations